AEON BIOPHARMA INC (AEON)
AMEXHealth CareBiotechnologySnapshot 2026-09-04
$0.24-5.46%
Close 2026-09-04 · 1-day change
AMEXHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · AEON
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance sits well below its industry cohort — worth keeping an eye on, though it has not freshly broken.
One-year growth currently built into the price, compared with our model's estimate.
A comparable price-assumption read is not available for this company.
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
No outside relationship met the current evidence threshold.
Based on historical daily prices through 2026-09-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Worth watching into the next print: this name has erratic recent earnings surprises and is a smaller-cap name (higher miss base rate). A fundamental tilt, not a price call.
Model as of 2026-09-04 · Compared with 398 industry peers · Company calendar date is not available
AEON — litigation filed
Dated 2026-08-03
Other Events. On August 3, 2026, the Company received a letter from NYSE Regulation confirming that the Company has regained compliance with the continued listing standards of NYSE American. The letter stated that the Company is in compliance with all of the NYSE American continued listing standards set forth in Part 10 of the NYSE American Company Guide (the “Company Guide”). Specifically, the Company resolved the previously identified deficiencies under Sections 1003(a)(i) and 1003(a)(ii)…
Why it matters: Compliance with NYSE rules is crucial for AEON's stock listing. Failure to comply could lead to delisting.
Worry ifManagement says they fixed compliance issues with the NYSE.
Less concerning ifThere are more delays or problems with NYSE compliance issues.
Why it matters: Sector growth trends can impact AEON's performance. Slowing growth may affect investor sentiment.
Watch forSector revenue growth remains above its median.
Also watch forSector revenue growth drops below its median.
Why it matters: Successful capital raises help with cash flow and operations. Investors care about how money is used.
Supportive ifManagement says they completed a private placement. They raised a lot of money.
Worry ifNo news or delays in the private placement process are reported.
Why it matters: This meeting is key for getting feedback on the next steps for ABP-450's approval. Positive feedback can boost confidence in the product's path to market.
Supportive ifAEON formally requests a Type 2b meeting with the FDA in 2026.
Worry ifAEON does not request the Type 2b meeting as planned.
We watch for confirming and disproving signals on each item. Resolutions are found automatically where possible and checked by hand for unclear cases. Last 90 days shown.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$263 on $10,000 · ±2.6% | How much price usually moves either way. |
| Bad day | $938 loss on $10,000 · 9.4% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $8,628 loss on $10,000 · 86.3% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Why it matters: Finishing this program is key for ABP-450 to get full approval. It shows the product is ready for the market.
Supportive ifAEON says it will finish most of its program in 2026.
Worry ifAEON says there are big delays in the program.
Why it matters: Maintaining this level is essential for compliance with NYSE listing standards. It reflects the company's financial health and stability.
Supportive ifAEON says stockholder equity is above $4 million in its next report.
Worry ifStockholder equity drops below $4 million in the next report.
Why it matters: Improving cash flow signals better financial health. It is key to AEON's future.
Supportive ifQ2 earnings report shows cash flow from operations turning positive.
Worry ifThe Q2 earnings report shows cash flow from operations is still negative.
Why it matters: The success of the public offering can improve cash flow and support growth plans.
Supportive ifThey said they raised money from the public offering.
Worry ifThey announced low demand or did not raise the expected money.
Why it matters: This feedback will clarify the next steps for ABP-450's development. Positive feedback could speed up the approval process.
Supportive ifThe FDA gave clear rules for clinical studies on ABP-450 after the BPD Type 2b meeting.
Worry ifThe FDA says big changes are needed for the ABP-450 development plan.
Why it matters: Having good cash helps with development and operations. It shows financial health.
Supportive ifCash and cash equivalents plus financing confirm funds will last into early 2027.
Worry ifThe cash position drops a lot, which may cause liquidity problems before 2027.
Why it matters: Using these warrants could give more money for ABP-450's development. It shows investor trust.
Supportive ifMilestone warrants are used, bringing in $34 million in total.
Worry ifNo milestone warrants are used. This shows that investors are not very interested.
Why it matters: Maintaining compliance is crucial for AEON's stock listing. Non-compliance could lead to delisting.
Worry ifAEON meets NYSE American listing standards. It does this without any problems.
Less concerning ifAEON gets new non-compliance notices from NYSE American.